• Phase 3 osteoarthritis trial completed, results expected Q2 2026
• Phase 2 aGvHD trial enrolment completed, results expected Q2 2026
• Phase 1/2 kidney transplantation trial progressing to second cohort

Cynata Therapeutics provided a quarterly update, highlighting progress across its leading clinical programs. The company completed patient enrolment and key activities in the Phase 3 osteoarthritis trial, known as SCUlpTOR, with results expected in Q2 2026. Enrolment was also completed in the Phase 2 trial of CYP-001 in acute graft versus host disease (aGvHD), with results anticipated around June 2026. In parallel, the first cohort of the Phase 1/2 NEREID kidney transplantation trial was completed following a positive independent DSMB review, with no safety concerns or episodes of transplant rejection identified, and the trial will now progress with the second cohort of patients. Cynata continued to strengthen its intellectual property portfolio, securing several patent allowances and grants across the US and Europe. The company ended the quarter with a cash balance of ~$2.6m, which was subsequently boosted to ~$3.8m following a further ~$1.2m raised via the ATM facility. Cynata is now focused on upcoming data readouts and next-stage development planning, with multiple clinical and strategic catalysts anticipated over the period ahead.

Cynata is entering a period focused on the analysis and reporting of clinical data from its leading programs, with two major efficacy trials nearing completion. The company expects to report results from both its Phase 3 osteoarthritis trial and Phase 2 aGvHD trials in Q2 CY 2026, which will inform the next stage of development and strategic decision-making. Alongside these readouts, Cynata will continue active engagement with regulatory authorities to clarify potential approval pathways and development requirements. The company is also preparing for next-stage clinical and commercial planning across its pipeline, including evaluation of partnering, licensing and regional development opportunities where appropriate.